Neurocrine Biosciences Inc., of San Diego, said it started a Phase IIb trial testing elagolix, an oral gonadotropin-releasing hormone antagonist, in uterine fibroids

Despite positive Phase II data, Paris-based Sanofi SA and San Diego-based Vical Inc

after the San Diego firm licensed North American development and commercialization rights to the compound, paying BioLineRx $30 million up front and potentially $335 million in milestones

Mast Therapeutics Inc., of San Diego, said the European Commission designated MST-188 (purified poloxamer 188) as an orphan medicinal product for the treatment of sickle cell disease

OncoSec Medical Inc., of San Diego, reported positive, durable response results in an update on interim data from its Phase II metastatic melanoma trial of its ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors...Trius Therapeutics Inc., of San Diego, reported top-line results from its ESTABLISH 2 Phase III study of tedizolid phosphate (TR-701) in acute bacterial skin and skin structure infections (ABSSSI), including methicillin-resistant Staphylococcus aureus (MRSA

Other Opinions Issued by CHMP Baxter International Inc., of London, and Halozyme, of San Diego, received a positive opinion on HyQvia (solution for subcutaneous use) for primary and secondary immunodeficiencies

San Diego) McMaster University Collaboration To characterize the in vivo advantages and potential clinical impact of Genoa's lead program, inhaled GP-101 in idiopathic pulmonary fibrosis The research will combine Genoa's expertise in aerosol drug delivery with McMaster's experience in exploring mechanisms of pulmonary fibrosis and managing patients with IPF 1/17/13 Intrexon Corp. (Germantown, Md.) Sanford-Burnham Medical Research Institute (La Jolla, Calif.) Collaboration To accelerate stem cell

Acadia Pharmaceuticals Inc., of San Diego, presented results from its pivotal Phase III -020 study with pimavanserin in patients with Parkinson's disease psychosis, with the analysis of the full dataset from the study showing robust and consistent efficacy of pimavanserin across a wide array of study measures and confirming the positive top-line results previously reported...MediciNova Inc., of San Diego, reported data from a Phase Ib/IIa study of MN-166 (ibudilast) in opioid withdrawal and

Upsher-Smith Laboratories Inc., of Maple Grove, Minn., presented data at the American Academy of Neurology meeting in San Diego, supporting favorable tolerability and a predictable, consistent pharmacokinetic profile of USL255 at high doses following single-dose administration to healthy subjects

after the San Diego firm licensed North American development and commercialization rights to the compound, paying BioLineRx $30 million up front and potentially $335 million in milestones

Adamas Pharmaceuticals Inc., of Emeryville, Calif., presented results for Nurelin (amantadine HCL extended-release capsules) in traumatic brain injury at the American Academy of Neurology annual meeting in San Diego, showing that the drug has additional therapeutic applications beyond its initial indication in levodopa-induced dyskinesia...International Stem Cell Corp., of Carlsbad, Calif., reported positive data from a study of safety and efficacy of human parthenogenic stem cells in a primate

San Diego-based Vical Inc., with the immunotherapy Allovectin

Data were presented at the American Academy of Neurology meeting in San Diego...Data, presented at the American Academy of Neurology meeting in San Diego, indicated that Plegridy significantly reduced MS disease activity, including relapses, disability progression and brain lesions, compared to placebo at one year

Chelsea Therapeutics International Ltd., of Charlotte, N.C., said it will present results from Northera (droxidopa) Study 306 at the American Academy of Neurology 65th Annual Meeting, taking place March 16-23, in San Diego...Impax Pharmaceuticals, of Hayward, Calif., a division of Impax Laboratories Inc., disclosed the presentation of results from its Rytary (IPX066) Phase III and open-label extension trials at the 65th Annual Meeting of the American Academy of Neurology in San Diego on March 18

Newron Pharmaceuticals SpA and its partner, Zambon SpA, remain on track to file for approval for safinamide as add-on therapy in Parkinson's disease in the fourth quarter, following the release of pivotal Phase III data at the annual meeting of the American Academy of Neurology in San Diego this week

Newron Pharmaceuticals SpA and its partner, Zambon SpA, remain on track to file for approval for safinamide as add-on therapy in Parkinson's disease in the fourth quarter, following the release of pivotal Phase III data at the annual meeting of the American Academy of Neurology in San Diego this week

Santarus Inc., of San Diego, published results from its Phase III (CORE II) study of Uceris (budesonide) extended-release tablets for ulcerative colitis in the gut...Trevena Inc., King of Prussia, Pa., said that Phase I, first-in-man studies of TRV130 will be presented at the American Academy of Neurology meeting in San Diego, March 19

Visionary Pharmaceuticals Inc., of San Diego, obtained a Phase I Small Business Innovation Research award to develop small-molecule retinoic acid-related orphan receptor (ROR) modulators targeting TH17 T-lymphocytes in inflammatory bowel disease

The New York-based company has more than 20 programs across the network of labs that are located in San Diego, San Francisco, Boston and New York...J&J also has a no-strings-attached incubator within its San Diego Janssen Labs facility to house biotech startups. (See BioWorld Today, October 18, 2011.) "It's an experiment to begin with, but has really demonstrated the power of relationship building," Keeney said